Pilot Study of Dornase Alfa (Pulmozyme) Therapy for Acquired Ventilator Associated Infection in Preterm and Late Preterm Infants in the Neonatal Intensive Care Unit

Trial Profile

Pilot Study of Dornase Alfa (Pulmozyme) Therapy for Acquired Ventilator Associated Infection in Preterm and Late Preterm Infants in the Neonatal Intensive Care Unit

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Dornase alfa (Primary)
  • Indications Neonatal respiratory distress syndrome; Respiratory tract infections
  • Focus Therapeutic Use
  • Acronyms PVAIN
  • Most Recent Events

    • 15 Dec 2017 Planned End Date changed from 1 Dec 2015 to 1 Apr 2017.
    • 18 May 2017 Status changed from active, no longer recruiting to completed.
    • 06 Aug 2015 Planned End Date changed from 31 May 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top